+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Cost effectiveness of home based population screening for Chlamydia trachomatis in the UK: economic evaluation of chlamydia screening studies (ClaSS) project



Cost effectiveness of home based population screening for Chlamydia trachomatis in the UK: economic evaluation of chlamydia screening studies (ClaSS) project



BMJ 335(7614): 291



To investigate the cost effectiveness of screening for Chlamydia trachomatis compared with a policy of no organised screening in the United Kingdom. Economic evaluation using a transmission dynamic mathematical model. Central and southwest England. Hypothetical population of 50,000 men and women, in which all those aged 16-24 years were invited to be screened each year. Cost effectiveness based on major outcomes averted, defined as pelvic inflammatory disease, ectopic pregnancy, infertility, or neonatal complications. The incremental cost per major outcome averted for a programme of screening women only (assuming eight years of screening) was 22,300 pounds (33,000 euros; $45,000) compared with no organised screening. For a programme screening both men and women, the incremental cost effectiveness ratio was approximately 28,900 pounds. Pelvic inflammatory disease leading to hospital admission was the most frequently averted major outcome. The model was highly sensitive to the incidence of major outcomes and to uptake of screening. When both were increased the cost effectiveness ratio fell to 6200 pound per major outcome averted for screening women only. Proactive register based screening for chlamydia is not cost effective if the uptake of screening and incidence of complications are based on contemporary empirical studies, which show lower rates than commonly assumed. These data are relevant to discussions about the cost effectiveness of the opportunistic model of chlamydia screening being introduced in England.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052368071

Download citation: RISBibTeXText

PMID: 17656504

DOI: 10.1136/bmj.39262.683345.ae


Related references

Effectiveness and cost-effectiveness of a pharmacy-based screening programme for Chlamydia trachomatis in a high-risk health centre population in Amsterdam using mailed home-collected urine samples. International Journal of Std & Aids 15(12): 797-802, 2004

Cost effectiveness analysis of a population based screening programme for asymptomatic Chlamydia trachomatis infections in women by means of home obtained urine specimens. Sexually Transmitted Infections 77(4): 276-282, 2001

Cost-effectiveness of screening programs for Chlamydia trachomatis: a population-based dynamic approach. Sexually Transmitted Diseases 27(9): 518-529, 2000

A population based dynamic approach for estimating the cost effectiveness of screening for Chlamydia trachomatis. Sexually Transmitted Infections 79(5): 426, 2003

Cost effectiveness analysis of a population based screening programme for asymptomatic Chlamydia trachomatis infection in women. Sexually Transmitted Infections 78(1): 76, 2002

Does population screening for Chlamydia trachomatis raise anxiety among those tested? Findings from a population based chlamydia screening study. Bmc Public Health 6: 106, 2006

Opportunistic screening for genital infections with Chlamydia trachomatis in sexually active population of Amsterdam. II. Cost-effectiveness analysis of screening women. Nederlands Tijdschrift Voor Geneeskunde 143(13): 677-681, 1999

Opportunistic screening for genital infections with Chlamydia trachomatis among the sexually active population in Amsterdam. III. Cost-effectiveness analysis of screening women and the role of reinfection and partner treatment. Nederlands Tijdschrift Voor Geneeskunde 143(47): 2383-2385, 1999

Performance and cost-effectiveness of selective screening criteria for Chlamydia trachomatis infection in women. Implications for a national Chlamydia control strategy. Sexually Transmitted Diseases 24(3): 131-141, 1997

Cost effectiveness of screening for Chlamydia trachomatis: a review of published studies. Sexually Transmitted Infections 78(6): 406-412, 2002

Population prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae in the Netherlands. Should asymptomatic persons be tested during population-based Chlamydia screening also for gonorrhoea or only if chlamydial infection is found?. Bmc Infectious Diseases 6: 42, 2006

Screening for Chlamydia trachomatis infection using the BdprobeTec Et Chlamydia trachomatis amplified Dna assay on urine in a Gum clinic setting: a simple, fast and cost-effective alternative. International Journal of Std & Aids 12(7): 430-436, 2001

Screening for Chlamydia trachomatis infection using the BDProbeTecTM ET Chlamydia trachomatis amplified DNA assay on urine in a GUM clinic setting: A simple, fast and cost-effective alternative. International Journal of STD & AIDS 12(7): 430-436, 2001

Should asymptomatic men be included in chlamydia screening programs? Cost-effectiveness of chlamydia screening among male and female entrants to a national job training program. Sexually Transmitted Diseases 35(1): 91-101, 2008

Cost-effectiveness analysis of Chlamydia trachomatis screening via internet-based self-collected swabs compared with clinic-based sample collection. Sexually Transmitted Diseases 38(9): 815-820, 2013